Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Non-Current Deferred Tax Liability (2009 - 2025)

Grifols' (GRFS) quarterly Non-Current Deferred Tax Liability came in at $1.0 billion in Q4 2025, down 7.32% YoY from $1.1 billion in Q4 2024, and down 7.32% on a QoQ basis from $1.1 billion in Q4 2024.

Grifols (GRFS) Non-Current Deferred Tax Liability (2009 - 2025) Analysis & Trends

Grifols (GRFS) has 17 years of Non-Current Deferred Tax Liability data on file, last reported at $1.0 billion in Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 7.32% year-over-year to $1.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 billion (down 7.32% YoY) and the FY2025 annual result came in at $1.0 billion, down 7.32% from the prior year.
  • Non-Current Deferred Tax Liability declined to $1.0 billion in Q4 2025, from $1.1 billion in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 billion in Q4 2024 to a low of $725.3 million in Q4 2021.
  • A 5-year average of $985.7 million and a median of $1.1 billion in 2022 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 45.57% — and 2025, when it decreased 7.32%.
  • Tracing GRFS's Non-Current Deferred Tax Liability over 5 years: stood at $725.3 million in 2021, then surged by 45.57% to $1.1 billion in 2022, then gained by 0.75% to $1.1 billion in 2023, then advanced by 1.67% to $1.1 billion in 2024, then declined by 7.32% to $1.0 billion in 2025.
  • The last three Non-Current Deferred Tax Liability figures came in at $1.0 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Grifols 5.45 Bn 4.45 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.00 Bn
Dec 31, 2025 1.00 Bn
Dec 31, 2024 1.08 Bn
Dec 31, 2024 1.08 Bn
Dec 31, 2023 1.06 Bn
Dec 31, 2023 1.06 Bn
Dec 31, 2022 1.06 Bn
Dec 31, 2022 1.06 Bn
Dec 31, 2021 725.26 Mn
Dec 31, 2021 725.26 Mn
Dec 31, 2020 663.88 Mn
Dec 31, 2020 663.88 Mn
Dec 31, 2019 377.23 Mn
Dec 31, 2019 377.23 Mn
Dec 31, 2018 333.13 Mn
Dec 31, 2018 333.13 Mn
Jun 30, 2018 470.02 Mn
Jun 30, 2018 470.02 Mn
Dec 31, 2017 457.92 Mn
Dec 31, 2017 457.92 Mn